estimated $818 billion, or more than 1% of global gross domestic product. It is expected that the economic burden of AD will increase along with the anticipated rise in prevalence. 1, 2 The cholinergic deficit hypothesis for AD has been a major therapy target. 3 Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) are believed to improve cognitive impairment in mild to moderate AD by inhibiting neuronal acetylcholine breakdown. 4 Galantamine is unique in its additional ability to modulate nicotinic receptor activity. 4 Another hypothesis for neuronal loss and subsequent cognitive impairment in AD is glutamatergic-mediated excitatory cytotoxicity. 3 The cognitive enhancer memantine is believed to block flow-through channels of N-methyl-d-aspartate receptors-glutamate receptors involved in cognition. 5 Although the safety and efficacy of cognitive-enhancing medications have been examined in previous systematic reviews, only randomized controlled trials (RCTs) were included, limiting applicability of the findings to real world people. Furthermore, a network metaanalysis (NMA) has not been conducted. NMA provides summary treatment effects for pairwise treatment comparisons even if these treatments have never been compared directly in a study and provides the opportunity to rank each included treatment for the outcome examined. [6] [7] [8] NMA involves the simultaneous analysis of direct evidence from headto-head comparisons of the treatments of interest and indirect evidence-when the treatments of interest are compared through one or more common treatment comparators. 9, 10 For example, consider the scenario of a headto-head study directly comparing Treatment A with placebo and a head-to-head study directly comparing Treatment B with placebo. An indirect treatment effect estimate comparing A with B can be inferred based on the treatment effects of A versus placebo and B versus placebo (where placebo is the common treatment comparator). The potential utility of NMA and the generalizability of its results rest on the validity of the required assumptions. 11 Transitivity is a critical NMA assumption that the included trials have similar characteristics across treatment comparisons. 6, 12, 13 The statistical notion of transitivity is the consistency assumption, in which different sources of evidence (e.g., direct and indirect evidence) are in agreement before analyzing them jointly. The validity of the consistency assumption is fundamental to the reliability of the results. NMAs are being found in increasing numbers in the literature because of their ability to examine all potential treatments. 14 We examined the comparative effectiveness and safety of these agents in the treatment of individuals with AD through a systematic review and NMA.
METHODS

Protocol
A protocol was registered with PROSPERO (CRD42012001948) and published; 15 the methods are reported briefly here. We used the Preferred Reporting Items for Systematic reviews and Meta-Analysis Statement for NMA (Appendix S2). 16 
Eligibility Criteria
Studies of individuals with AD comparing donepezil, galantamine, rivastigmine, or memantine in any combination with each other or control (no treatment, placebo, best supportive care) were included. Studies examining other cognitive enhancers or including individuals with mixed dementia were excluded. Eligible studies had to report at least one of:
• Cognition (Mini-Mental State Examination (MMSE) (minimal clinically important difference (MCID) has been reported as a 3.50-to 3.95-point increase) 17 • Alzheimer's Disease Assessment Scale cognition subscale (ADAS-Cog) (MCID has been reported as a 3.1-to 3.8-point reduction) 18 • Function (Alzheimer's Disease Cooperative Study activity of daily living inventory (ADCS-ADL)) • Behavior (Neuropsychiatric Inventory (NPI)) (MCID has been reported as an 8-point reduction) 19 • Global status (Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus)) (MCID has been reported as a 1-point reduction) 20 • Mortality • Harms, including serious adverse events (those leading to disability or hospitalization or are life-threatening or fatal), bradycardia, falls, headaches, vomiting, diarrhea, and nausea A panel of 32 relevant clinicians and policy-makers from Health Canada selected outcomes. 21 RCTs, quasi-RCTs (participants are allocated to groups using nonrandom methods, e.g., consecutive appearance, day of the week, last digit of the health card), and nonrandomized studies (e.g., interrupted time series, controlled before-and-after studies, cohort studies) were eligible.
Information Sources and Literature Search
A librarian searched MEDLINE, EMBASE, Cochrane Methodology Register, Cochrane Central Register of Controlled Trials, CINAHL, and Ageline from inception until January 2015; searches were updated on March 9, 2016. Another librarian peer-reviewed the draft MEDLINE literature search. Unpublished studies were sought through conference proceedings, clinical trial registries, and author contact. Reference lists of included studies and relevant reviews were scanned.
Study Selection and Abstraction Process
After a training exercise, two team members independently screened and data abstracted the literature search results; conflicts were resolved through discussion. Authors were contacted to obtain clarifications on study eligibility or provide data clarifications. AD severity was classified according to MMSE scores using the National Institute for Health and Care Excellence categories: mild (21) (22) (23) (24) , moderate (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , severe (<10). 22 
Risk-of-Bias Appraisal
Two reviewers independently appraised the risk of bias (ROB) using the Cochrane ROB Tool for RCTs and quasi-RCTs; 23 the Cochrane Effective Practice and Organisation of Care ROB Tool for non-RCTs, interrupted time series, and controlled before-and-after studies; 24 and the Newcastle-Ottawa Scale for cohort studies. 25 Publication bias and small-study effects were examined visually using comparison-adjusted funnel plots under the fixed-effect model, 26 with treatments ordered chronologically according to year of availability in Canada and basic parameters plotted using the control group (or oldest treatment when missing) as the common comparator, decreasing correlations that multi-arm trials induce.
Synthesis
Bayesian random-effects pairwise metaanalysis was conducted for each treatment comparison and outcome, because we anticipated clinical and methodological heterogeneity. Odds ratios (ORs) were used for dichotomous outcomes, and to facilitate clinical interpretation, mean differences (MDs) were used for continuous outcomes instead of standardized mean difference. Missing measures of variance (e.g., standard deviations) were imputed. 27 Random-effects Bayesian NMA was conducted for each outcome that formed a connected network diagram using OpenBUGS version 3.2.3, revision 1012 28 and assuming common within-network between-study variance (s 2 ). A common between-study variance parameter was assumed, because all the treatments are pharmacological. For studies that examined different dosages of the same medication in different treatment arms, dosages selected for analysis were consistent with those approved for use in Canada (File S1 in Appendix S1). Transitivity was assessed by exploring potential treatment effect modifiers using tables of participant and study characteristics. Consistency was assessed for the entire network using the design-bytreatment interaction model 29 in Stata (Stata Corp., College Station, TX) using the network command. 30 When global inconsistency was observed, each closed loop was assessed separately using the loop-specific method with common within-loop s 2 . 31 If inconsistency was observed, the data were checked for discrepancies, and if none were identified, the following additional analyses were considered:
• Subgroup analysis (SGA) on age (<75 vs ≥75), AD severity, cardiac comorbidity for falls and bradycardia outcomes • Metaregression on study duration assuming a common fixed coefficient across treatment comparisons • Sensitivity analysis (SA) on ROB (allocation concealment, incomplete outcome data), studies with imputations, and study design
The surface under the cumulative ranking (SUCRA) curve was used to rank treatments 32 and was displayed in a rank-heat plot. 33 For pairwise meta-analysis and NMA models, the Markov Chain Monte Carlo method was used to calculate median treatment effects and 95% credible intervals (CrIs). Noninformative prior distributions were adopted for all parameters in the model and a half-normal prior distribution for between-study standard deviation (s~Ν (0, 1), s>0). For each treatment effect, we also calculated the 95% predictive interval, capturing the magnitude of the within-network between-study variance. 34 
RESULTS
Literature Search
The literature search yielded 20,343 titles and abstracts, of which 1,958 articles were potentially relevant, and their full-text was reviewed ( Figure 1) ; 205 studies, including 63 companion reports, were included (citations presented in File S2 in Appendix S1). Twelve of these were written in languages other than English. Four were conference abstracts. In total, 33 authors were contacted, and eight of the 19 who responded provided data usable for analysis.
Study and Participant Characteristics
The studies (110 RCTs, 21 non-RCTs, 11 cohort studies) were published between 1996 and 2015 ( Tables 1, 2 and S1 in Appendix S1); number of participants ranged from 13 to 2,045, average age ranged from 61 to 88, and percentage female ranged from 3% to 89%.
Risk of Bias
Using the Cochrane ROB Tool (Table S2 , Figure S1 in Appendix S1), 60% of the RCTs had unclear adequate allocation concealment, and 70% had selective outcome reporting. Overall, 53% were at high risk of incomplete outcome data bias because of a large number of drop-outs, and 56% had a high potential risk of "other" bias (e.g., funding bias).
Most of the 21 non-RCTs had unclear ROB due to blinding, contamination, and selective outcome reporting on the Cochrane Effective Practice and Organisation of Care ROB Tool (Table S3 , Figure S2 in Appendix S1). Methodological shortcomings in the cohort studies according to the Newcastle-Ottawa Scale (Table S4 , Figure S3 in Appendix S1) included using a somewhat-representative exposed cohort, failing to adjust for important confounders, and not reporting the number of participants who were lost to follow-up. The comparison-adjusted funnel plots indicated no evidence of publication bias or small-study effects ( Figure S4 in Appendix S1), and all of the analyses upheld the transitivity assumption (Table S5 in Appendix S1).
NMA Results
The statistically significant results (identified as "superior" herein) of NMA for each outcome are provided in this article, with a focus on RCTs. All additional analyses for each outcome (including analyses including all study designs) are available in Data S1 in Appendix S1. The complete results of each outcome analysis and treatment comparisons are reported in Tables S6 and S7 in Appendix S1.
Cognition
The NMA on the MMSE included 56 RCTs, eight treatments, and 10,446 participants ( Figure S5A in Appendix S1). Only donepezil (MD = 1.39, 95% CrI = 0.53-2.24), donepezil+memantine (MD = 2.59, 95% CrI = 0.12-4.98), and transdermal rivastigmine (MD = 2.02, 95% CrI = 0.02-4.08) were superior to placebo (Table S8 , Figure S6A in Appendix S1). Donepezil+ memantine had the greatest likelihood of being the most effective in improving MMSE scores according to the SUCRA (88%, Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
The NMA on the ADAS-Cog included 53 RCTs, six treatments, and 11,348 participants ( Figure S5B in Appendix S1). Only donepezil (MD = À3.29, 95% CrI = À4.57 to À1.99) and galantamine (MD = À2.13, 95% CrI = À3.91 to À0.27) were superior to placebo (Table S8 , Figure S6B in Appendix S1). Donepezil had the greatest likelihood of being the most effective in improving ADAS-Cog scores according to the SUCRA (83%, Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Function
The NMA of functional status (ADCS-ADL) included 15 RCTs, nine treatments, and 4,249 participants and found that no treatments were superior to placebo ( Figure S5C , S6C in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Behavior
The NMA on behaviour (NPI) included 26 RCTs, 6 treatments, and 5,138 patients ( Figure S5D in Appendix S1). Donepezil + memantine significantly improved behavior on the NPI versus placebo (MD = À5.23, 95% CrI = À8.72, À1.56), donepezil alone (MD = À3.90, 95% CrI = À7.23, À0.56), galantamine (MD = À4.17, 95% CrI = À7.97, À0.29), and transdermal rivastigmine + memantine (MD = À9.99, 95% CrI = À17.78, À1.97) (Table S8, Figure S6D in Appendix S1). Donepezil + memantine had the greatest likelihood of being the most N = 20,343 titles and abstracts identified from MEDLINE, EMBASE, CINAHL, Ageline and other sources (e.g., expertnominated, reference lists, unpublished data) N = 18,385 excluded titles and abstracts:
• effective at improving behavior on the NPI according to the SUCRA (100%, Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Global Status
The NMA on global status (CIBIC-plus) included 16 RCTs, five treatments, and 4,564 participants ( Figure S5E in Appendix S1). Donepezil (MD = À0.32, 95% CrI = À0.46 to À0.19), donepezil+memantine (MD = À0.57, 95% CrI = À0.95 to À0.21), galantamine (MD = À3.79, 95% CrI = À6.98 to À0.59), and oral rivastigmine (MD = À0.38, 95% CrI = À0.56 to À0.17) were superior to placebo (Table S8, Figure S6E in Appendix S1). Galantamine was also superior to donepezil (MD = À3.47, 95% CrI = À6.66 to À0.26), oral rivastigmine (MD = À3.41, 95% CrI = À6.62 to À0.21), and transdermal rivastigmine (MD = À3.59, 95% CrI = À6.78 to À0.39) and had the greatest likelihood of being the most effective at improving global status on the CIBIC-plus according to the SUCRA (100%, Figure S7 in Appendix S1).
Mortality
The NMA on mortality included 34 RCTs, seven treatments, and 11,856 participants ( Figure S5F in Appendix S1). The overall control group mortality event rate was 0.02 (95% confidence interval (CI) = 0.01-0.04). The only treatment superior to placebo was galantamine (OR = 0.56, 95% CrI = 0.36-0.87; Table S8, Figure S6F in Appendix S1). The SUCRA value for galantamine was 71% ( Figure S7 in Appendix S1); SUCRAs for two therapies were greater (donepezil+memantine (86%) and transdermal rivastigmine (100%)). Results of additional analyses are available in Data S1 in Appendix S1. 
Serious Adverse Events
NMA was conducted on serious adverse events (defined in Table S9 in Appendix S1) with 48 RCTs, eight treatments, and 14,189 participants ( Figure S5G in Appendix S1). The overall control group SAEs event rate was 0.10 (95% CI = 0.08-0.14). No treatments were superior to placebo for this outcome ( Figure S6G in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Falls
NMA was conducted on falls with 15 RCTs, five treatments, and 4,643 participants ( Figure S5H in Appendix S1). The overall control group falls event rate was 0.05 (95% CI = 0.03-0.08). No treatments were superior to placebo ( Figure S6H in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Bradycardia
NMA on bradycardia included five RCTs, three treatments, and 1,290 participants ( Figure S5I in Appendix S1) and did not find any significant differences ( Figure S6 Panel I in Appendix S1). The overall control group bradycardia event rate was 0.02 (95% CI = 0.00-0.07).
Headache
NMA on headache included 40 RCTs, seven treatments, and 11,539 participants ( Figure S5J in Appendix S1). The overall control group headache event rate was 0.05 (95% CI = 0.03-0.07). Only oral rivastigmine caused more participants to experience headache than placebo (OR = 1.66, 95% CrI = 1.03-2.76) (Table S8, Figure S6J in Appendix S1). Oral rivastigmine+memantine had the greatest likelihood of being the safest therapeutic regimen for headache according to the SUCRA (100%, Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Diarrhea
NMA on diarrhea included 41 RCTs, five treatments, and 13,250 participants ( Figure S5K in Appendix S1). The overall control group diarrhea event rate was 0.05 (95% CI = 0.04-0.07). Only donepezil (OR = 1.62, 95% CrI = 1.24-2.16) and oral rivastigmine (OR = 1.87, 95% CrI = 1.18-3.06) had a greater risk of diarrhea than placebo (Table S8 , Figure S6K in Appendix S1). Memantine had the greatest likelihood of being the safest according to the SUCRA (100%, Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Vomiting
NMA on vomiting included 42 RCTs, six treatments, and 12,997 participants ( Figure S5L in Appendix S1). The overall control group vomiting event rate was 0.04 (95% CI = 0.03-0.06). Donepezil (OR = 1.76, 95% CrI = 1.11-2.80), galantamine (OR = 2.65, 95% CrI = 1.76-4.04), and oral rivastigmine (OR = 3.95, 95% CrI = 2.36-6.59) had a greater risk of vomiting than placebo ( (100%, Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
Nausea
NMA on nausea included 54 RCTs, seven treatments, and 16,039 participants ( Figure S5M in Appendix S1). The overall control group nausea event rate was 0.06 (95% CrI = 0.04-0.08). Donepezil (OR = 1.95, 95% CrI = 1.42-2.73), galantamine (OR = 2.96, 95% CrI = 2.13-4.13), and oral rivastigmine (OR = 3.59, 95% CrI = 2.47-5.29) had a greater risk of nausea than placebo (Table S8, Table S8 in Appendix S1); and donepezil+memantine had a lower risk of nausea than donepezil (OR = 0.10, 95% CrI = 0.00-0.88), galantamine (OR = 0.07, 95% CrI = 0.00-0.61), and oral rivastigmine (OR = 0.06, 95% CrI = 0.00-0.52). According to the SUCRA, donepezil+memantine (100%) and memantine (86%) had the greatest likelihood of being the safest (Figure S7 in Appendix S1). Results of additional analyses are available in Data S1 in Appendix S1.
DISCUSSION
Overall, our results suggest that, for all effectiveness outcomes, it is likely that donepezil+memantine is the most effective therapy, followed by donepezil and galantamine, although this must be interpreted with caution given that relatively few participants received this combination therapy in the studies. More important, the effect size met criteria for MCID only for donepezil for the ADAS-Cog cognition outcome. In addition, it is likely that the global status results were clinically relevant for galantamine. None of the cognitive enhancers alone or in combination were likely to improve participants' functional status. Some differences were noted in the results for the ADASCog and MMSE outcomes, which are probably because of the different studies (and sample sizes) included in these analyses. For example, donepezil+memantine (found to be superior to placebo for MMSE) was used in four studies (25 participants) for the outcome of MMSE but was not available for the ADAS-Cog analysis. Similarly, galantamine was compared with placebo in three studies (1,809 participants) for the MMSE analysis (not found to be superior to placebo) and in nine studies (2,924 participants) for the ADAS-Cog analysis (found to be superior to placebo). Donepezil was found to be superior to placebo for the MMSE analysis (24 studies, 3,740 participants) and for the ADAS-Cog analysis (21 studies, 3,293 participants).
We found that cholinesterase inhibitors increased the risk of gastrointestinal harms and headache. These harms are significant and caused substantial numbers of participants to drop out of the studies; 53% of the included RCTs were assessed as having a high risk of incomplete outcome data because of the large number of dropouts. The control group event rates suggest that, on average, approximately 4-6 of every 100 individuals will experience gastrointestinal harms. For all safety outcomes, it is likely that placebo was the safest, followed by memantine, and oral rivastigmine was most likely to cause the most harm. Although it is likely that donepezil+memantine was the most-effective therapy, it was not ranked the safest and was ranked the least safe for headache.
Four Cochrane reviews have examined cognitive enhancers for AD [35] [36] [37] [38] and found that donepezil, 35, 38 galantamine, 35, 36 and rivastigmine 35, 37 improved cognition, which is consistent with our results. In addition, two of the reviews 36, 37 found that galantamine and rivastigmine improved global status, which is also in agreement with our findings. Similar to our results, these reviews found that cognitive enhancers increased risk of gastrointestinal harm. Our results differed from these reviews with respect to improvement of function with donepezil and rivastigmine 37, 38 and behavior with donepezil and galantamine. 36, 38 Our review used NMA to be able to compare the effectiveness of medications with one another and was more comprehensive in including nonrandomized study designs, as well as combinations of medications. Our searches were more comprehensive and up to date because we included 111 studies with 22,117 participants not previously included in these Cochrane reviews (Table S10 in  Appendix S1 ).
An important characteristic of the included trials is that dementia is a progressive disease, and many of the trials use the last-observation-carried-forward strategy for intention-to-treat analysis when data were missing. Given that there are more drop-outs from participants allocated to receive cognitive enhancers than placebo, this analysis could lead to bias favoring finding a positive outcome on cognition. 39 The participants included in the RCTs, and thus in our analyses, may be heterogeneous, and as such, the cognitive effects observed here might be an overestimation, although the transitivity assumption was upheld when we compared the treatment effect estimates for treatment comparisons for different participant characteristics. We also explored potential treatment effect modifiers such as age and disease severity (Data S1 in Appendix S1). In addition, most of the included studies had a short duration of follow-up, although our metaregression analysis did not detect any differences in results after controlling for study duration. Although our ROB appraisal identified limitations, most of the results were consistent when restricting inclusion to RCTs with low risk of allocation concealment bias and incomplete outcome data bias. Clinicians and patients need to consider whether the differences in outcomes are clinically important; only donepezil met the MCID for cognition and galantamine for global assessment. Finally, clinicians need to reflect on how the MCID might change with disease severity, as this has also been postulated.
Our work has further limitations. We were unable to include some studies because the authors did not provide data in a usable format. We contacted 33 authors, and eight of the 19 who responded gave us data we could include in our NMAs. In addition, we did not examine outcomes such as quality of life and admission to longterm care because we focused on including outcomes that our policy-maker and healthcare provider partners nominated. We also did not include population-based observational studies that investigated harms associated with cognitive enhancers in older individuals with mixed types of dementia that were not specific to AD. 40, 41 These observational studies found an association between cholinesterase inhibitor use and bradycardia, pacemaker insertion, hip fracture secondary to falls, and syncope. It has been suggested that participants in RCTs of cognitive enhancers might be a healthier population than those receiving these medications in the real world. 42 Furthermore, the predictive intervals of some of the outcomes examined here were wider than the CrIs, suggesting that there is uncertainty regarding the effect size and CrI for these results. For example, the result of a future study may have a CrI containing the neutral value 0 for the MD and 1 for the OR. SUCRA values can be unreliable 43 and thus need to be interpreted alongside the effect sizes and 95% CrIs. Finally, we were not able to examine dosages in our NMA because many of the studies reported only a dosage range.
CONCLUSION
In conclusion, it is likely that donepezil+memantine, donepezil, and galantamine are the most-effective agents for AD of the effectiveness outcomes examined here. These improvements were clinically relevant for changes in global status for galantamine. For cognition, only donepezil reached the MCID threshold on the ADAS-Cog scale and thus is likely a first choice for individuals and clinicians considering these agents. We found no greater risk of serious harms, falls, or bradycardia in individuals with AD, although cholinesterase inhibitors caused more participants to experience headache, diarrhea, nausea, and vomiting, which may result in poor quality of life and cessation of therapy. In addition, longer-term observational studies of cognitive enhancers used in practice might identify greater risk of adverse events in individuals with multiple comorbidities and those who are using the medications over many years. Future research can focus on an individual patient data NMA, 44 which can be used to produce treatment recommendations for specific individual characteristics.
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